Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OGA | O60502 | 4/20 | 0.37 |
| ▸ | PIM1 | P11309 | 1/20 | 0.34 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.34 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.34 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.34 |
| ▸ | CSNK2A3 | Q8NEV1 | 1/20 | 0.34 |
| ▸ | STAT3 | P40763 | 2/20 | 0.33 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.33 |
| ▸ | LGALS8 | O00214 | 1/20 | 0.33 |
| ▸ | LGALS3 | P17931 | 1/20 | 0.33 |
| ▸ | LGALS4 | P56470 | 1/20 | 0.33 |
| ▸ | MGAM | O43451 | 2/20 | 0.33 |
| ▸ | SI | P14410 | 2/20 | 0.33 |
| ▸ | PYGB | P11216 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14228011 | 1.00 | OGA (0.37) | OGAPIM1CSNK2A2CSNK2BCSNK2A1 | |
| SCHEMBL14199486 | 1.00 | OGA (0.37) | OGAPIM1CSNK2A2CSNK2BCSNK2A1 | |
| SCHEMBL662016 | 1.00 | OGA (0.37) | OGAPIM1CSNK2A2CSNK2BCSNK2A1 | |
| SCHEMBL6142431 | 1.00 | OGA (0.37) | OGAPIM1CSNK2A2CSNK2BCSNK2A1 | |
| SCHEMBL13497166 | 1.00 | OGA (0.37) | OGAPIM1CSNK2A2CSNK2BCSNK2A1 | |
| SCHEMBL18533110 | 1.00 | OGA (0.37) | OGAPIM1CSNK2A2CSNK2BCSNK2A1 | |
| SCHEMBL9999673 | 1.00 | OGA (0.37) | OGAPIM1CSNK2A2CSNK2BCSNK2A1 | |
| SCHEMBL12154805 | 1.00 | OGA (0.37) | OGAPIM1CSNK2A2CSNK2BCSNK2A1 | |
| SCHEMBL8045018 | 1.00 | OGA (0.37) | OGAPIM1CSNK2A2CSNK2BCSNK2A1 | |
| SCHEMBL9843877 | 1.00 | OGA (0.37) | OGAPIM1CSNK2A2CSNK2BCSNK2A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100249394-A1 | PROCESSES FOR PRODUCING DECITABINE | ALBEMARLE CORPORATION (US) | 2010-09-30 | — | — | US | claimed |
| US-7361745-B2 | Process for the preparation of 1-chloro-3,5-di-o-acyl-2-deoxy-l-ribofuranoside derivatives | INALCO S.P.A. (IT) | 2008-04-22 | — | — | US | claimed |
| US-20070083041-A1 | Process for the preparation of 1-chloro-3,5-di-o-acyl-2-deoxy-l-ribofuranoside derivatives | INALCO, S.P.A. (IT) | 2007-04-12 | — | — | US | claimed |
| EP-1699805-A1 | PROCESS FOR THE PREPARATION OF 1-CHLORO-3,5-DI-O-ACYL-2-DEOXY-L-RIBOFURANOSIDE DERIVATIVES | Inalco S.p.A. (IT) | 2006-09-13 | — | — | EP | claimed |
| WO-2005044832-A1 | PROCESS FOR THE PREPARATION OF 1-CHLORO-3,5-DI-O-ACYL-2-DEOXY-L-RIBOFURANOSIDE DERIVATIVES | INALCO S.P.A. (IT) | 2005-05-19 | — | — | WO | claimed |
| US-5585252-A | CATALYTIC ACYLATION OF ALCOHOLS | G. D. SEARLE & CO. (US) | 1996-12-17 | — | — | US | claimed |
| CN-117098767-A | METTL3 modulators | 埃克森特治疗公司 | 2023-11-21 | — | — | CN | disclosed |
| WO-2022081739-A1 | METTL3 MODULATORS | ACCENT THERAPEUTICS, INC. (US) | 2022-04-21 | — | — | WO | disclosed |
| EP-3184112-B1 | SYNTHETIC INTERMEDIATE OF 1-(2-DEOXY-2-FLUORO-4-THIO-ß-D-ARABINOFURANOSYL)CYTOSINE | FUJIFILM CORP (JP) | 2020-12-23 | — | — | EP | disclosed |
| CN-107011168-B | Synthesis intermediates of cytosines and synthesis intermediates of thionucleosides | 富士胶片株式会社 | 2020-06-09 | — | — | CN | disclosed |
| US-10570112-B2 | Synthetic intermediate of 1-(2-deoxy-2-fluoro-4-thio-β-D-arabinofuranosyl)cytosine, synthetic intermediate of thionucleoside, and method for producing the same | FUJIFILM CORPORATION (JP) | 2020-02-25 | — | — | US | disclosed |
| US-20180327377-A1 | SYNTHETIC INTERMEDIATE OF 1-(2-DEOXY-2-FLUORO-4-THIO-ß-D-ARABINOFURANOSYL)CYTOSINE, SYNTHETIC INTERMEDIATE OF THIONUCLEOSIDE, AND METHOD FOR PRODUCING THE SAME | FUJIFILM CORPORATION (JP) | 2018-11-15 | — | — | US | disclosed |
| US-10093645-B2 | Synthetic intermediate of 1-(2-deoxy-2-fluoro-4-thio-β-D-arabinofuranosyl)cytosine, synthetic intermediate of thionucleoside, and method for producing the same | FUJIFILM CORPORATION (JP) | 2018-10-09 | — | — | US | disclosed |
| EP-0357009-A2 | Method of resolution of hydroxy-cyclopentenones using a lipase and transacylation agents | G.D. Searle & Co. (US) | 1990-03-07 | — | — | EP | disclosed |
| EP-0357571-A2 | Pyrimidine nucleosides | Medivir Aktiebolag (SE) | 1990-03-07 | — | — | EP | disclosed |
| US-4898936-A | ANTITUMOR AGENTS | PCR, INC. (US) | 1990-02-06 | — | — | US | disclosed |
| WO-1989012061-A1 | PYRIMIDINE NUCLEOSIDES AND INTERMEDIATES | MEDIVIR AB (SE) | 1989-12-14 | — | — | WO | disclosed |
| EP-0195805-A4 | PROCESS FOR MAKING A 2-DEOXYURIDINE. | SCM CORP (US) | 1987-07-09 | — | — | EP | disclosed |
| EP-0195805-A1 | PROCESS FOR MAKING A 2-DEOXYURIDINE | PCR, Inc. (US) | 1986-10-01 | — | — | EP | disclosed |
| WO-1986001801-A1 | PROCESS FOR MAKING A 2-DEOXYURIDINE | SCM CORPORATION (US) | 1986-03-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10093645-B2 | Synthetic intermediate of 1-(2-deoxy-2-fluoro-4-thio-β-D-arabinofuranosyl)cytosine, synthetic intermediate of thionucleoside, and method for producing the same | TYMS, TYMP, RRM2B | OGA 673/4885PIM1 3829/4885CSNK2A2 3355/4885 |
| US-10570112-B2 | Synthetic intermediate of 1-(2-deoxy-2-fluoro-4-thio-β-D-arabinofuranosyl)cytosine, synthetic intermediate of thionucleoside, and method for producing the same | TYMS, TYMP, RRM2B | OGA 673/4885PIM1 3829/4885CSNK2A2 3355/4885 |
| US-20180327377-A1 | SYNTHETIC INTERMEDIATE OF 1-(2-DEOXY-2-FLUORO-4-THIO-ß-D-ARABINOFURANOSYL)CYTOSINE, SYNTHETIC INTERMEDIATE OF THIONUCLEOSIDE, AND METHOD FOR PRODUCING THE SAME | TYMS, TYMP, RRM2B | OGA 687/4885PIM1 3838/4885CSNK2A2 3310/4885 |
| US-20070083041-A1 | Process for the preparation of 1-chloro-3,5-di-o-acyl-2-deoxy-l-ribofuranoside derivatives | RNGTT, RNASEL, CPSF7 | OGA 209/4885PIM1 2119/4885CSNK2A2 2378/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.